LNTH · Lantheus Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.54B | $1.53B | $1.30B | $935.06M | $425.21M | $339.41M |
| Cost of Revenue | $599.66M | $545.62M | $586.89M | $353.36M | $237.51M | $200.65M |
| Gross Profit | $941.95M | $988.29M | $709.54M | $581.70M | $187.69M | $138.76M |
| R&D | $177.31M | $168.10M | $77.71M | $311.68M | $44.97M | $32.79M |
| SG&A | $275.12M | $193.69M | $125.46M | $133.58M | $150.40M | $69.27M |
| Total Operating Expenses | - | - | - | - | - | $142.96M |
| D&A | - | - | - | - | - | $23.25M |
| Operating Income | $310.83M | $456.98M | $364.64M | $36.20M | ($60.83M) | ($4.20M) |
| Interest Expense | $19.75M | $19.67M | $20.02M | $7.18M | $7.75M | $9.48M |
| Income Tax | $80.23M | $118.53M | $84.28M | ($1.35M) | ($3.76M) | $1.99M |
| Net Income | $233.56M | $312.44M | $326.66M | $28.07M | ($71.28M) | ($13.47M) |
| EPS - Basic | $3.46 | $4.52 | $4.79 | $0.41 | ($1.06) | ($0.25) |
| EPS - Diluted | $3.41 | $4.36 | $4.65 | $0.40 | ($1.06) | ($0.25) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $359.12M | $912.81M | $713.66M | $415.65M | $98.51M | $79.61M |
| Accounts Receivable | $358.64M | $321.26M | $284.29M | $213.40M | $89.34M | $54.00M |
| Inventory | $64.67M | $68.03M | $64.03M | $35.48M | $35.13M | $35.74M |
| Accounts Payable | $42.91M | $34.56M | $41.19M | $20.56M | $20.79M | $16.28M |
| Current Assets | $899.96M | $1.33B | $1.09B | $677.62M | $235.79M | $184.22M |
| Total Assets | $2.23B | $1.98B | $1.65B | $1.32B | $863.78M | $869.82M |
| Current Liabilities | $333.42M | $240.53M | $187.35M | $247.70M | $90.50M | $80.50M |
| Long-term Debt | - | - | - | $557.71M | $163.12M | $197.70M |
| Total Liabilities | $1.14B | $892.33M | $835.26M | $874.11M | $399.35M | $355.62M |
| Stockholders' Equity | $1.09B | $1.09B | $815.89M | $447.15M | $464.44M | $514.21M |
| Retained Earnings | $679.50M | $445.94M | $133.50M | ($193.16M) | ($221.22M) | ($149.95M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $390.14M | $544.75M | $305.26M | $281.78M | $53.92M | $16.40M |
| Investing Cash Flow | ($627.17M) | ($226.01M) | $5.94M | ($276.55M) | $3.68M | ($4.91M) |
| Financing Cash Flow | ($316.58M) | ($118.54M) | ($13.06M) | $311.69M | ($39.33M) | ($21.86M) |
| CapEx | - | - | $45.34M | $260.00M | $12.14M | $12.47M |
| Free Cash Flow | - | - | $259.92M | $21.78M | $41.78M | $3.92M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 61.1% | 64.4% | 54.7% | 62.2% | 44.1% | 40.9% |
| Operating margin | 20.2% | 29.8% | 28.1% | 3.9% | -14.3% | -1.2% |
| EBITDA margin | - | - | - | - | - | 5.6% |
| Net margin | 15.2% | 20.4% | 25.2% | 3.0% | -16.8% | -4.0% |
| Free cash flow margin | - | - | 20.0% | 2.3% | 9.8% | 1.2% |
| FCF / Net income | - | - | 0.80 | 0.78 | -0.59 | -0.29 |
| R&D / Revenue | 11.5% | 11.0% | 6.0% | 33.3% | 10.6% | 9.7% |
| SG&A / Revenue | 17.8% | 12.6% | 9.7% | 14.3% | 35.4% | 20.4% |
| Effective tax rate | 25.6% | 27.5% | 20.5% | -5.0% | - | - |
| Return on assets | 10.5% | 15.8% | 19.8% | 2.1% | -8.3% | -1.5% |
| Return on equity | 21.4% | 28.7% | 40.0% | 6.3% | -15.3% | -2.6% |
| Return on invested capital | - | - | - | 3.6% | -7.7% | -0.5% |
| Liquidity | ||||||
| Current ratio | 2.70 | 5.52 | 5.80 | 2.74 | 2.61 | 2.29 |
| Quick ratio | 2.51 | 5.23 | 5.45 | 2.59 | 2.22 | 1.84 |
| Cash ratio | 1.08 | 3.80 | 3.81 | 1.68 | 1.09 | 0.99 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 1.25 | 0.35 | 0.38 |
| Debt / Assets | - | - | - | 0.42 | 0.19 | 0.23 |
| Debt / EBITDA | - | - | - | - | - | 10.38 |
| Interest coverage | 15.7x | 23.2x | 18.2x | 5.0x | -7.8x | -0.4x |
| Equity multiplier | 2.04 | 1.82 | 2.02 | 2.95 | 1.86 | 1.69 |
| Liabilities / Assets | 0.51 | 0.45 | 0.51 | 0.66 | 0.46 | 0.41 |
| Efficiency | ||||||
| Asset turnover | 0.69 | 0.77 | 0.79 | 0.71 | 0.49 | 0.39 |
| Inventory turnover | 9.27 | 8.02 | 9.17 | 9.96 | 6.76 | 5.61 |
| Days sales outstanding | 85d | 76d | 80d | 83d | 77d | 58d |
| Days inventory outstanding | 39d | 46d | 40d | 37d | 54d | 65d |
| Days payable outstanding | 26d | 23d | 26d | 21d | 32d | 30d |
| Cash conversion cycle | 98d | 99d | 94d | 99d | 99d | 93d |
| Valuation | ||||||
| P / E | 19.5x | 20.5x | 13.3x | 127.4x | - | - |
| P / B | 4.2x | 5.9x | 5.3x | 8.1x | 4.2x | 1.4x |
| P / S | 3.0x | 4.2x | 3.4x | 3.9x | 4.6x | 2.2x |
| EV / EBITDA | - | - | - | - | - | 44.5x |
| Growth | ||||||
| Revenue growth (YoY) | 0.5% | 18.3% | 38.6% | 119.9% | 25.3% | 2.4% |
| Revenue CAGR (3y) | 18.1% | 53.4% | 56.3% | 41.3% | 7.4% | 0.8% |
| Revenue CAGR (5y) | 35.3% | 35.9% | 30.4% | 23.1% | 7.1% | 2.4% |
| Gross profit growth (YoY) | -4.7% | 39.3% | 22.0% | 209.9% | 35.3% | -20.6% |
| Operating income growth (YoY) | -32.0% | 25.3% | 907.4% | - | -1348.9% | - |
| Net income growth (YoY) | -25.2% | -4.4% | 1063.9% | - | -429.1% | - |
| EPS growth (YoY) | -21.8% | -6.2% | 1062.5% | - | -324.0% | - |
| EPS CAGR (3y) | 104.3% | - | - | -20.3% | - | - |
| EPS CAGR (5y) | - | 40.7% | 35.2% | -33.9% | - | - |
| FCF growth (YoY) | - | - | 1093.3% | -47.9% | 965.2% | -93.3% |
| FCF CAGR (5y) | - | - | 44.6% | -7.5% | -0.2% | -14.6% |
| Book value growth (YoY) | 0.2% | 33.4% | 82.5% | -3.7% | -9.7% | 348.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$4.57B totalProduct$1.51B · 33.0%
PYLARIFY$989.12M · 21.7%
Radiopharmaceutical Oncology$989.12M · 21.7%
Total Precision Diagnostics$493.11M · 10.8%
Definity$330.25M · 7.2%
Techne Lite$86.80M · 1.9%
Strategic Partnerships And Other$59.38M · 1.3%
Neuraceq$51.45M · 1.1%
Licenseand Royalty Revenues$34.04M · 0.7%
Other Precision Diagnostics$24.62M · 0.5%
Geographic
$1.54B totalUS$1.46B · 94.6%
Non Us$82.73M · 5.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.97
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Lantheus Holdings against the 5 most active filers in the same SIC group.